Literature DB >> 3569359

Increased serum prolactin but normal TSH during prolonged domperidone treatment in children.

A R Deprettere, K J Van Acker, M V Du Caju.   

Abstract

The influence of the dopamine receptor blocking agent domperidone on prolactin and TSH secretion was studied in 16 infants, aged 10-360 days, who were treated for gastroesophageal reflux. The pretreatment serum prolactin levels were not statistically different from the levels in age-matched controls and showed the well-known inverse relationship with age. During treatment with domperidone a significant increase in prolactin level was observed on days 1, 4 and 21-28, the mean values on these three days not being statistically different. No correlation could be found between the serum prolactin levels and the corresponding plasma domperidone levels. One infant of this series and three not included in this series developed reversible breast hypertrophy with galactorrhoea in three of them: in none of them was the prolactin level, corrected for age, above 1 SD of the mean. All had received relatively high doses of domperidone. In 13 patients domperidone did not influence TSH secretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3569359     DOI: 10.1007/bf02343232

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  Serum prolactin levels in humans from birth to adult life.

Authors:  H J Guyda; H G Friesen
Journal:  Pediatr Res       Date:  1973-05       Impact factor: 3.756

2.  Gynecomastia in a male infant given domperidone.

Authors:  M van der Steen; M V Du Caju; K J Van Acker
Journal:  Lancet       Date:  1982-10-16       Impact factor: 79.321

3.  Galactorrhoea as side effect of domperidone.

Authors:  P A Cann; N W Read; C D Holdsworth
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-30

4.  Domperidone, an extracerebral inhibitor of dopamine receptors, stimulates thyrotropin and prolactin release in man.

Authors:  G Delitala; L Devilla; G Lotti
Journal:  J Clin Endocrinol Metab       Date:  1980-06       Impact factor: 5.958

5.  Effect of domperidone on prolactin (PRL)and thyrotrophin (TSH) secretion.

Authors:  J M Kaufman; A Elewaut; A Vermeulen
Journal:  Arch Int Pharmacodyn Ther       Date:  1981-12

6.  Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress.

Authors:  J Nagler; P Miskovitz
Journal:  Am J Gastroenterol       Date:  1981-12       Impact factor: 10.864

7.  Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man.

Authors:  J R Sowers; B Sharp; R W McCallum
Journal:  J Clin Endocrinol Metab       Date:  1982-04       Impact factor: 5.958

8.  Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects.

Authors:  F Massara; F Camanni; A Amoroso; G M Molinatti; E E Müller
Journal:  Acta Endocrinol (Copenh)       Date:  1981-05

9.  Effects of domperidone therapy on symptoms and upper gastrointestinal motility in infants with gastroesophageal reflux.

Authors:  B B Grill; A C Hillemeier; L A Semeraro; R W McCallum; J D Gryboski
Journal:  J Pediatr       Date:  1985-02       Impact factor: 4.406

  9 in total
  3 in total

1.  Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child.

Authors:  Luc M Hondeghem; Noël H Logghe
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

2.  Gastro-oesophageal reflux in infants. Evaluation of treatment by pH monitoring.

Authors:  Y Vandenplas; L Sacré-Smits
Journal:  Eur J Pediatr       Date:  1987-09       Impact factor: 3.183

Review 3.  A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN).

Authors:  Y Vandenplas; A Ashkenazi; D Belli; N Boige; J Bouquet; S Cadranel; J P Cezard; S Cucchiara; C Dupont; K Geboes
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.